Circumstances of prescription of hormone therapy for patients with prostate cancer;Circonstances de prescription de l'hormonothérapie chez des patients atteints de cancer de la prostate

Progres en Urologie

Volumn 19, Issue 5, 2009, Pages 313-320

  de la Taille, A ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

GnRH analog; Hormonotherapy; Prostate cancer; Urologist

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DRUG DERIVATIVE; GONADORELIN;

AGED; ARTICLE; HUMAN; MALE; PRESCRIPTION; PROSTATE TUMOR; STATISTICS;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; DRUG PRESCRIPTIONS; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 64749083999     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.purol.2009.01.009     Document Type: Article

References (16)

1. Belot A., Grosclaude P., Bossard N., Jougla E., Benhamou E., Delafosse P., et al. Cancer incidence and mortality in France over the period 1980-2005. Rev Epidemiol Sante Publique 56 (2008) 159-175
2. Villers A., Soulié M., and Culine S. Epidémiologie et dépistage du cancer de la prostate. Oncologie 6 (2004) 245-250
3. Fournier G., Valeri A., Mangin P., and et Cussenot O. Cancer de la prostate. Traitement. Ann Urol 38 (2004) 225-258
4. Seidenfeld J., Samson D.J., Hasselblad V., Aronson N., Albertsen P.C., Bennett C.L., et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 132 (2000) 566-577
5. Tombal B., Tajeddine N., and Van Cangh P.-J. Traitement du cancer de la prostate. Place de l'hormonothérapie en 2003. Louvain Med 122 (2003) S58-S67
6. Guise T.A., Oefelein M.G., Eastham J.A., Cookson M.S., Higano C.S., and Smith M.R. Estrogenic side effects of androgen deprivation therapy. Rev Urol 9 (2007) 163-180
7. Soulié M., et al. Recommandations 2007 en onco-urologie. Prog Urol 17 (2007) 1130-1159
8. Peneau M., Piechaud T., Cariou G., Ragni E., Fontaine E., and Fournier G. Clinical stage T3 prostate cancer. Natural history, treatment options and results. Prog Urol 8 (1998) 977-993
9. Holmberg L., Bill-Axelson A., Helgesen F., Salo J.O., Folmerz P., Haggman M., et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 347 (2002) 781-789
10. Bouchot O. Prise en charge du cancer métastatique de la prostate en 2006 : état de l'Art. Prog Urol 16 (2006) 671-674
11. Han M., Partin A.W., Zahurak M., Piantadosi S., Epstein J.I., and Walsh P.C. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169 (2003) 517-523
12. D'Amico A.V., Chen M.H., Renshaw A.A., et al. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. Jama 299 (2008) 289-295
13. Smith M.R., O'Malley A.J., and Keating N.L. Gonadotrophin-releasing hormone agonists, diabetes and cardiovascular disease in men with prostate cancer: which metabolic syndrome?. BJU Int 101 (2008) 1335-1336
14. Lu-Yao G.L., Albertsen P.C., Moore D.F., et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 300 (2008) 173-181
15. Studer UE, Whelan P, Albrecht W, et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. http://www.ncbi.nlm.nih.gov/pubmed/16622261?ordinalpos=5&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum. J Clin Oncol. 2006;24:1868-76.
16. Studer U.E., Whelan P., Albrecht W., et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 24 (2006) 1868-1876